Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2011 Oct 25;11(1):119–131. doi: 10.1158/1535-7163.MCT-11-0510

Figure 4.

Figure 4

(A) Western blot analysis of SART1 expression and PARP cleavage in HCT116 cells transfected with control (−) or SART1 (+) siRNAs and co-treated with 5-FU (IC30(48h)) or SN38 (IC30(48h)) for 24 and 48 h. (B, C and D) Flow cytometric analyses of apoptosis following SART1 silencing alone or in combination with either 5-FU (IC30(48h)) or SN38 (IC30(48h)) in HCT116 (B), RKO (C) and LS147T (D). All cells were reversed transfected with SART1 siRNA for 24h prior to a 48h treatment with chemotherapy.